Recruitment

Recruitment Status
Enrolling by invitation
Estimated Enrollment
Same as current

Summary

Conditions
Chronic Plaque Psoriasis
Type
Interventional
Phase
Phase 3
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 2 years and 125 years
Gender
Both males and females

Description

This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis

This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis

Tracking Information

NCT #
NCT04286607
Collaborators
Not Provided
Investigators
Study Director: David Berk, MD Arcutis Biotherapeutics, Inc.